Danish Pharmacovigilance Update, Archive
-
Danish Pharmacovigilance Update 28 November 2013
| 03 February 2014 |
In this issue of Danish Pharmacovigilance Update: Ciprofloxacin and the risk of tendon disorders, risk of blood clots from the use of the cancer medicine ponatinib and reporting of adverse reactions to the Danish Health and Medicines Authority.
-
Danish Pharmacovigilance Update, 26 September 2013
| 21 November 2013 |
In this issue of Danish Pharmacovigilance Update: Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are associated with risk of capillary leak syndrome.
-
Danish Pharmacovigilance Update, 29 August 2013
| 23 October 2013 |
In this issue of Danish Pharmacovigilance Update: Cases of acquired haemophilia following treatment with clopidogrel (Plavix® etc.)
-
Danish Pharmacovigilance Update, 27 June 2013
| 24 July 2013 |
In this issue of Danish Pharmacovigilance Update: The benefits of medicines for the treatment of acne (Diane® Mite and others) continue to outweigh the risks of use within the indication.
-
Danish Pharmacovigilance Update, 23 May 2013
| 17 June 2013 |
In this issue of Danish Pharmacovigilance Update: Cases of necrotising fasciitis associated with the use of bevacizumab (Avastin®).
-
Danish Pharmacovigilance Update, 25 April 2013
| 29 May 2013 |
In this issue of Danish Pharmacovigilance Update: Cerebral haemorrhage in association with the use of methylphenidate (Ritalin® etc.).
-
Danish Pharmacovigilance Update, 21 March 2013
| 25 April 2013 |
In this issue of Danish Pharmacovigilance Update: Depressive and suicidal thoughts following discontinuation of varenicline (Champix®).
-
Danish Pharmacovigilance Update, 21 February 2013
| 25 April 2013 |
In this issue of Danish Pharmacovigilance Update: Cardiovascular monitoring when initiating and re-initiating treatment with fingolimod (Gilenya®).
-
Danish Pharmacovigilance Update, 17 January 2013
| 26 March 2013 |
In this issue of Danish Pharmacovigilance Update: The Pharmacovigilance Risk Assessment Committee, PRAC, finds that the risks outweigh the benefits from the use of Tredaptive®